C

    Calidi Biotherapeutics Inc. (CLDI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.34
    +0.02 (+1.52%)

    Market Cap: $3.41M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(3/9)
    Avg Surprise
    -67.11%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-N/A---
    Jun 26
    		$-2.94N/AN/ABeat-988.9%
    Sep 25
    		$-2.21$-1.68-31.55%Miss+71.7%
    Jun 25
    		$-1.99$-1.32-50.76%Miss+88.2%
    Mar 25
    		$-2.25$-1.80-25.00%Miss+90.5%
    Dec 24
    		$-0.27$-0.09-200.00%Miss+43.7%
    Sep 24
    		$-7.80$-10.26+23.98%Beat+87.7%
    Jun 24
    		$-16.80$-17.40+3.45%Beat-3788.0%
    Mar 24
    		$-23.71$-32.40+26.82%Beat+12.3%
    Dec 23
    		$-0.48$-0.20-140.00%Miss-84.6%
    Sep 23
    		$-63.43$-20.40-210.93%Miss-317250.0%
    Jun 23
    		$-0.43N/AN/ABeat-408.6%
    Mar 23
    		$-27.02N/AN/ABeat-54148.2%
    Dec 22
    		$-0.26$0.00N/AMiss-273.3%
    Sep 22
    		$0.02$0.00N/ABeat+166.7%
    Jun 22
    		$0.14$0.00N/ABeat-
    Mar 22
    		$0.05$0.00N/ABeat-
    Dec 21
    		$0.15$0.00N/ABeat-
    Sep 21
    		$-0.03$0.00N/AMiss-
    Jun 21
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.14EV/EBITDA-1.64x
    Price/FCF-0.11xFCF Yield-940.48%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-672.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-112.69x
    Current Ratio1.68xQuick Ratio1.68x
    Trading Statistics
    Beta1.33Avg Volume147.35K
    52-Week High$27.8452-Week Low$1.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.33
    SMA 20$1.49
    SMA 50$1.84
    SMA 200$8.84
    EMA 10$1.37
    EMA 20$1.47
    EMA 50$1.93
    EMA 200$14.64

    MACD

    Line: -0.15Signal: -0.17Hist: 0.01

    ADX

    ADX: 45.3+DI: 8.4-DI: 4.4

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down8.0
    PSAR$0.73

    Bollinger Bands

    Upper Band$1.87
    Lower Band$1.11
    %B Position5112%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    38.4

    Momentum Oscillators

    Stoch %K16.7
    Stoch %D14.9
    Williams %R-76.7
    ROC (10d)-1.5%
    Momentum-0.02
    CCI (20d)-60.7
    MFI (14d)31.4

    Volatility Measures

    ATR (14d)$0.49(36.5%)
    StdDev (20d)0.19
    Hist Vol97.7%(High)

    Volume Flow

    VWAP$1.34
    OBV628.1M
    AD Line958.1B
    CMF (20d)-0.066

    Volume Metrics

    Avg Vol (20d)141.5K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.56

    Pivot Points

    R3$1.46
    R2$1.41
    R1$1.37
    Pivot Point$1.32
    S1$1.28
    S2$1.23
    S3$1.19

    Advanced Oscillators

    TSI-26.43
    Ultimate Osc48.9
    KST-258.59

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.50M$0$0$0$0$0
    Cost of Revenue$0$0$423,000$0$0$0$393,000$0$0$0$364,000$0
    Gross Profit$0$0$-423,000$0$0$0$-393,000$0$0$0$-364,000$0
    Operating Expenses$4.15M$4.19M$4.47M$5.05M$5.66M$5.06M$4.03M$5.23M$5.77M$6.75M$9.82M$7.22M
    R&D$2.56M$2.59M$2.36M$2.36M$2.59M$2.42M$1.81M$2.15M$2.17M$2.74M$0$3.25M
    SG&A$1.59M$1.60M$2.11M$2.69M$3.07M$2.64M$2.21M$3.07M$3.60M$4.01M$0$3.97M
    Operating Income$-4,150,000$-4,187,000$-4,466,000$-5,048,000$-5,664,000$-5,062,000$-4,026,000$-5,226,000$-5,772,000$-6,752,000$-9,820,000$-7,221,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$35,000$38,000$42,000$41,000$52,000$72,000$175,000$232,000$273,000$253,000$0$795,000
    Income Before Tax$-4,155,000$-4,104,000$-4,061,000$-5,171,000$-5,757,000$-5,059,000$-4,145,000$-5,070,000$-5,759,000$-7,221,000$-8,232,000$-2,013,000
    Income Tax Expense$5,000$4,000$-2,000$10,000$4,000$3,000$3,000$-1,000$8,000$4,000$-3,000$11,000
    Net Income$-4,160,000$-4,108,000$-4,059,000$-5,181,000$-5,761,000$-5,062,000$-4,148,000$-5,069,000$-5,767,000$-7,225,000$-8,229,000$-2,024,000
    EBITDA$-3,682,000$-3,640,000$-3,840,000$-4,703,000$-5,298,000$-4,593,000$-3,573,000$-4,439,000$-5,092,000$-6,578,000$-9,735,000$-672,000
    EBIT$-4,120,000$-4,066,000$-4,263,000$-5,130,000$-5,705,000$-4,987,000$-3,970,000$-4,838,000$-5,486,000$-6,968,000$-9,820,000$-1,218,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLDI

    News

    Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year

    Calidi Biotherapeutics (CLDI) reported that director Scott Leftwich received a grant of 4,000 non-qualified stock options with an exercise price of $1.36 per share. These options will vest in monthly installments over one year, starting from the August 17, 2026 grant date, and will expire on August 17, 2036. This grant was issued under the company's 2023 Equity Incentive Plan as part of its non-employee director compensation policy.

    Stock Titan•8/20/26•
    Neutral

    Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term

    Calidi Biotherapeutics (CLDI) has granted its Chief Financial Officer, Jackson Andrew C., 14,000 incentive stock options. These options have an exercise price of $1.36 per share, matching the closing price on August 17, 2026, and a 10-year term expiring on August 17, 2036. The vesting schedule involves 25% vesting on the one-year anniversary and the remaining 75% in 36 equal monthly installments, contingent on continued service.

    Stock Titan•8/20/26•
    Neutral

    Calidi Biotherapeutics (CLDI) grants director 5,000 options

    Calidi Biotherapeutics, Inc. (CLDI) reported that director James A. Schoeneck was granted 5,000 non-qualified stock options on August 17, 2026, with an exercise price of $1.36 per share. These options, issued under the company's 2023 Equity Incentive Plan, vest monthly over one year and expire on August 17, 2036. Following this grant, Schoeneck directly holds these 5,000 options, excluding any previously granted.

    Stock Titan•8/19/26•
    Neutral

    Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading

    Calidi Biotherapeutics, Inc. (CLDI) director George Peoples was granted 4,000 non-qualified stock options on August 17, 2026, with an exercise price of $1.36 per share. These options expire on August 17, 2036, and will vest monthly over one year under the company's 2023 Equity Incentive Plan and non-employee director compensation policy. The grant is detailed in a Form 4 filing, which clarifies that these holdings do not include previously granted options.

    Stock Titan•8/19/26•
    Neutral

    Calidi Biotherapeutics (CLDI) CEO awarded 32K options vesting over 4 years

    Calidi Biotherapeutics (CLDI) CEO Eric E. Poma was granted 32,000 incentive stock options under the company's 2023 Equity Incentive Plan. These options have an exercise price of $1.36, equal to the closing price on the August 17, 2026 grant date, and will vest over four years based on his continued service. The grant is exempt under Rule 16b-3 and does not include previously awarded options.

    Stock Titan•8/19/26•
    Neutral

    Frequently Asked Questions About CLDI

    Does CLDI pay dividends?
    Calidi Biotherapeutics Inc. (CLDI) does not currently pay a regular dividend.
    What is CLDI's market cap?
    Calidi Biotherapeutics Inc. (CLDI) has a market capitalization of $3.41M with a current stock price of $1.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In